Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun 18;11(6):970-975.
doi: 10.18240/ijo.2018.06.12. eCollection 2018.

Macular pigment and serum zeaxanthin levels with Goji berry supplement in early age-related macular degeneration

Shang Li  1 , Na Liu  2 , Li Lin  3 , Er-Dan Sun  2 , Jian-Da Li  2 , Peng-Kun Li  2
Affiliations

Macular pigment and serum zeaxanthin levels with Goji berry supplement in early age-related macular degeneration

Shang Li et al. Int J Ophthalmol. .

Abstract

Aim: To evaluate the efficacy of Goji berry supplementation on improving macular pigment, serum zeaxanthin levels and visual acuity in patients with early age-related macular degeneration (AMD).

Methods: A total of 114 patients (aged from 51 to 92y, mean age 69.53±8.41y) with early AMD were enrolled in our prospective, randomized controlled study. The included patients were assigned randomly to the Goji group (n=57) with 25 g of Goji berries supplementation per day for 90d and the control group (n=57) with their normal diet for 90d. Macular pigment optical density (MPOD) was measured using heterochromatic flicker photometry (HFP). The levels of serum lutein (L)/zeaxanthin (Z) were analyzed using high-performance liquid chromatography (HPLC). MPOD, serum L/Z levels and best corrected visual acuity (BCVA) were recorded at baseline and 90d.

Results: In the Goji group, there were no statistically significant differences in the serum L levels between the baseline (0.199±0.149 µmol/mL) and 90d (0.203±0.181 µmol/mL) (t=-0.186, P=0.850); however the serum Z levels were increased at 90d (0.101±0.087 µmol/mL) compared with those at the baseline (0.029±0.032 µmol/mL) (t=6.412, P<0.001). Patients treated with Goji berry for 90d showed an elevated MPOD (0.877±0.202 DU) from the baseline (0.731±0.205 DU) (t=-4.741, P=0.000). In contrast to the control group, the serum Z levels and MPOD were higher in the Goji group at 90d (both P<0.05). At 90d, patients with Goji berry supplementation had a relative decrease in BCVA (0.21±0.18 logMAR) compared with the baseline (0.27±0.20) (t=2.397, P=0.020).

Conclusion: Overall, daily supplementation with Goji berry for 90d improves MPOD by increasing serum Z levels rather than serum L levels in early AMD patients. Goji berry may be an effective therapeutic intervention for preventing the progression of early AMD.

Keywords: Goji berry; early age-related macular degeneration; zeaxanthin.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Representative of color fundus photography and OCT photographs in early AMD patients
A, B: Fundus and OCT photographs showed a soft distinct drusen at baseline; C, D: Fundus and OCT photographs showed that the drusen gradually diminished at the same position as arrowed after 90d of Goji berry supplementation.
Figure 2
Figure 2. The standard sample was used as a reference
Z1 (3R, 3′S)-zeaxanthin (0.522 µg/mL), Z2 (3R, 3′R)-zeaxanthin (0.398 µg/mL) and L (3R, 3′R, 6′R)-lutein (0.582 µg/mL) are arrowed.
Figure 3
Figure 3. Chromatogram of extracted serum from a single volunteer
Peaks of zeaxanthin and lutein (identified by comparison with injection of pure zeaxanthin and lutein) are arrowed.
Figure 4
Figure 4. Associations between serum Z levels and MPOD in the Goji group at 90d
The linear regression equation is Y(MPOD)=0.882-0.108X(serum Z levels).
See this image and copyright information in PMC

References

    1. Chew EY, Klein ML, Clemons TE, Agrón E, Ratnapriya R, Edwards AO, Fritsche LG, Swaroop A, Abecasis GR. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology. 2014;121(11):2173–2180. - PMC - PubMed
    1. Elfervig LS. Age-related macular degeneration. Nurse Pract Forum. 1998;9(1):4–6. - PubMed
    1. Chopdar A. Age related macular degeneration. BMJ. 2003;326(7387):485–488. - PMC - PubMed
    1. Subramanian ML, Ness S, Abedi G, Ahmed E, Daly M, Feinberg E, Bhatia S, Patel P, Nguyen M, Houranieh A. Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial. Am J Ophthalmol. 2009;148(6):875–882.e1. - PubMed
    1. Hollyfield JG. Age-related macular degeneration: the molecular link between oxidative damage, tissue-specific inflammation and outer retinal disease: the proctor lecture. Invest Ophthalmol Vis Sci. 2010;51(3):1275–1281. - PubMed

LinkOut - more resources